GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Indivior PLC (NAS:INDV) » Definitions » Cyclically Adjusted Price-to-FCF

Indivior (Indivior) Cyclically Adjusted Price-to-FCF : 14.48 (As of May. 24, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Indivior Cyclically Adjusted Price-to-FCF?

As of today (2024-05-24), Indivior's current share price is $17.37. Indivior's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $1.20. Indivior's Cyclically Adjusted Price-to-FCF for today is 14.48.

The historical rank and industry rank for Indivior's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

INDV' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 9.4   Med: 13.9   Max: 17.84
Current: 13.98

During the past years, Indivior's highest Cyclically Adjusted Price-to-FCF was 17.84. The lowest was 9.40. And the median was 13.90.

INDV's Cyclically Adjusted Price-to-FCF is ranked better than
82.05% of 312 companies
in the Drug Manufacturers industry
Industry Median: 33.315 vs INDV: 13.98

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Indivior's adjusted free cash flow per share data for the three months ended in Mar. 2024 was $-0.411. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $1.20 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Indivior Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Indivior's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Indivior Cyclically Adjusted Price-to-FCF Chart

Indivior Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 11.79

Indivior Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.95 14.79 14.73 11.79 17.84

Competitive Comparison of Indivior's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Indivior's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Indivior's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Indivior's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Indivior's Cyclically Adjusted Price-to-FCF falls into.



Indivior Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Indivior's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=17.37/1.2
=14.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indivior's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Indivior's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.411/131.7762*131.7762
=-0.411

Current CPI (Mar. 2024) = 131.7762.

Indivior Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 1.492 100.560 1.955
201409 0.839 100.428 1.101
201412 0.181 99.070 0.241
201503 1.140 99.621 1.508
201506 0.375 100.684 0.491
201509 0.368 100.392 0.483
201512 0.314 99.792 0.415
201603 0.636 100.470 0.834
201606 0.516 101.688 0.669
201609 0.585 101.861 0.757
201612 0.774 101.863 1.001
201703 0.347 102.862 0.445
201706 0.781 103.349 0.996
201709 0.174 104.136 0.220
201712 0.381 104.011 0.483
201803 0.120 105.290 0.150
201806 0.380 106.317 0.471
201809 0.687 106.507 0.850
201812 0.557 105.998 0.692
201903 0.879 107.251 1.080
201906 -0.417 108.070 -0.508
201909 0.251 108.329 0.305
201912 0.239 108.420 0.290
202003 -0.939 108.902 -1.136
202006 -0.013 108.767 -0.016
202009 0.168 109.815 0.202
202012 -0.466 109.897 -0.559
202103 0.570 111.754 0.672
202106 0.455 114.631 0.523
202109 0.867 115.734 0.987
202112 1.189 117.630 1.332
202203 -0.513 121.301 -0.557
202206 0.183 125.017 0.193
202209 0.423 125.227 0.445
202212 -0.132 125.222 -0.139
202303 -0.298 127.348 -0.308
202306 -0.140 128.729 -0.143
202309 -0.049 129.860 -0.050
202312 -2.133 129.419 -2.172
202403 -0.411 131.776 -0.411

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Indivior  (NAS:INDV) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Indivior Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Indivior's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Indivior (Indivior) Business Description

Industry
Traded in Other Exchanges
Address
234 Bath Road, Slough, Berkshire, GBR, SL1 4EE
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs based on buprenorphine for treatment of opioid dependence. The vast majority of Indivior's revenue is generated in the United States, followed by the rest of the world. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.